Michael C Rice MS, MBA
Mike heads Lumanity’s Advanced Therapies and Rare Diseases practices specializing in strategic development of platform technologies and applications for genetically defined patient populations and broad polygenic diseases. He also co-heads the hematologic oncology and cardiometabolics practices.
He has 25+ years of experience in biotech ventures supporting new company creation and defining strategic development and early commercial strategy for academic and biotech inventions pertaining to nucleic acids, gene therapy and cellular platforms applied across monogenetic diseases and oncology. Mike studied the molecular basis of cancer at the Kimmel Cancer Institute and is recognized for his extensive intellectual property and publication portfolio pertaining to recombinational DNA repair and molecular diagnostics. Mike is a co-inventor of non-nuclease gene editing methodology currently used commercially in agricultural trait improvement and in development for therapeutic applications.
Mike holds an MBA, with a concentration in Biotechnology from the Alfred Lerner School of Business and Economics, at the University of Delaware, an MS in Molecular Pharmacology from Thomas Jefferson University and a Bachelor of Science degree in Biology from the University of Delaware. Industry positions involved translational research, strategic planning, technology transfer, finance and business development.
Mike is a Member of the Pennsylvania Biotechnology Center Advisory Council, enjoys mentoring early-stage life science entrepreneurs and is a member of ASGCT, ARM, SITC, ASCO and AHA professional societies.